Role of IL-12 family cytokines in human autoimmune Uveitis
IL-12家族细胞因子在人类自身免疫性葡萄膜炎中的作用
基本信息
- 批准号:10019976
- 负责人:
- 金额:$ 47.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAdoptive ImmunotherapyAutoimmune DiseasesB-LymphocytesBloodBone MarrowCNS autoimmune diseaseCellsChIP-seqChronicCytokine SignalingDifferentiation and GrowthDiseaseFamilyGenetic EngineeringGoalsGreater sac of peritoneumHumanImmunityInflammatoryInterleukin-10Interleukin-12Lymphocyte FunctionMultiple SclerosisMusNeurodegenerative DisordersPathogenesisPlayRetinaRoleSpleenUveitisautoimmune uveitiscytokineexosomeinterleukin-23membernovelsingle-cell RNA sequencingtherapeutic cytokinestranscriptome
项目摘要
In this study, we investigated mechanisms by which regulatory B cells (Bregs) suppress CNS autoimmune diseases such as Uveitis or Multiple Sclerosis. These studies focused on Bregs that secrete IL-10, IL-27 or IL-35. We have isolated these Breg cells from human blood or bone marrow and in mice they were isolated from the spleen or peritoneal cavity. We are now characterizing the Breg cells transcriptomes by single-cell RNA-Seq (scRNA-Seq), Chip-Seq, ATAC-Seq. We have also isolated IL-35 containing exosomes from IL-35-producing Bregs (i35-Bregs), demonstrated that they suppress experimental autoimmune uveitis (EAU), suggesting that exosomes derived from Bregs can be exploited for adoptive immunotherapy in CNS autoimmune and neurodegenerative diseases.
在这项研究中,我们研究了调节性B细胞(Bregs)抑制CNS自身免疫性疾病(如葡萄膜炎或多发性硬化症)的机制。这些研究集中在分泌IL-10、IL-27或IL-35的Bregs。我们已经从人的血液或骨髓中分离出了这些Breg细胞,在小鼠身上,它们也是从脾或腹膜中分离出来的。我们现在正在用单细胞RNA-Seq(scRNA-Seq)、Chip-Seq、ATAC-Seq来鉴定Breg细胞的转录本。我们还从产生IL-35的Bregs(i35-Bregs)中分离出含有IL-35的外切体(i35-Bregs),证明它们可以抑制实验性自身免疫性葡萄膜炎(EAU),这表明Bregs来源的Exosome可以用于中枢神经系统自身免疫性和神经退行性疾病的过继免疫治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles E Egwuagu其他文献
Charles E Egwuagu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles E Egwuagu', 18)}}的其他基金
Interferon-inducible Transcription Factors: Roles In Ocu
干扰素诱导转录因子:在 Ocu 中的作用
- 批准号:
6507394 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
INTERFERON INDUCIBLE TRANSCRIPTION FACTORS: ROLES IN OCU
干扰素诱导转录因子:在 OCU 中的作用
- 批准号:
6414669 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Development of dendritic cell vaccine against uveitis
抗葡萄膜炎树突状细胞疫苗的研制
- 批准号:
6968529 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Development of dendritic cell vaccine against uveitis
抗葡萄膜炎树突状细胞疫苗的研制
- 批准号:
7139194 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Mechanisms of immune homeostasis and regulation of intraocular inflammation
免疫稳态机制和眼内炎症调节
- 批准号:
9155560 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Role of IL-12 family cytokines in human autoimmune Uveit
IL-12家族细胞因子在人类自身免疫性Uveit中的作用
- 批准号:
7321809 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Mechanisms of immune homeostasis and regulation of intraocular inflammation
免疫稳态机制和眼内炎症调节
- 批准号:
8339763 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Suppressors of Cytokine Signalling (SOCS) have Neuroprotective Roles in Retina
细胞因子信号传导抑制剂 (SOCS) 对视网膜具有神经保护作用
- 批准号:
8339752 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Suppressors of Cytokine Signalling (SOCS) have Neuroprotective Roles in Retina
细胞因子信号传导抑制剂 (SOCS) 对视网膜具有神经保护作用
- 批准号:
7594053 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
Mechanisms of immune homeostasis and regulation of intraocular inflammation
免疫稳态机制和眼内炎症调节
- 批准号:
10019987 - 财政年份:
- 资助金额:
$ 47.64万 - 项目类别:
相似海外基金
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
- 批准号:
10713034 - 财政年份:2023
- 资助金额:
$ 47.64万 - 项目类别:
Phase I first-in-human trial for ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
484371 - 财政年份:2023
- 资助金额:
$ 47.64万 - 项目类别:
Operating Grants
Phase I first-in-human trial of ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
473376 - 财政年份:2022
- 资助金额:
$ 47.64万 - 项目类别:
Operating Grants
Development of Adoptive Immunotherapy Focusing on Follicular Helper T Cell Biology
专注于滤泡辅助 T 细胞生物学的过继免疫疗法的发展
- 批准号:
21K16420 - 财政年份:2021
- 资助金额:
$ 47.64万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10180117 - 财政年份:2021
- 资助金额:
$ 47.64万 - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10364687 - 财政年份:2021
- 资助金额:
$ 47.64万 - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10599851 - 财政年份:2021
- 资助金额:
$ 47.64万 - 项目类别:
Development of a combinatorial approach of antibody therapeutics and adoptive immunotherapy for cancer
开发抗体疗法和癌症过继免疫疗法的组合方法
- 批准号:
21K19422 - 财政年份:2021
- 资助金额:
$ 47.64万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Elucidation of the function of the new NK cell subset and its application to adoptive immunotherapy
阐明新NK细胞亚群的功能及其在过继性免疫治疗中的应用
- 批准号:
21H04832 - 财政年份:2021
- 资助金额:
$ 47.64万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells
使用离体扩增的多肿瘤相关抗原特异性细胞毒性 T 细胞对成人 T 细胞白血病/淋巴瘤进行过继免疫治疗
- 批准号:
20K17375 - 财政年份:2020
- 资助金额:
$ 47.64万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




